Industry Workshops provide an opportunity for AMCP corporate members to showcase their latest drug therapies, technologies, and a wealth of products and services affecting professionals working in managed care pharmacy.
All Industry Workshops take place on Tuesday, Oct. 17, from noon–1pm.
What Lies Beneath: The Importance of Earlier Diagnosis and Care of Young Individuals with Duchenne Muscular Dystrophy
Room: Magnolia 2&3
Description: In this engaging discussion, experts from Sarepta Therapeutics will review several timely topics related to Duchenne muscular dystrophy: the rationale for prioritizing early diagnosis and intervention, ongoing newborn screening efforts and practices, the magnitude and impact of heterogeneity between patients, and why a one-size fits all approach to tracking patient outcomes is challenging.
Faculty:
Kathrin Kucharski, PharmD
Senior Director, Medical Managed Care
Sarepta Therapeutics
Erin O’Rourke, MS, CGC
Senior Director, Medical Affairs Diagnostics
Sarepta Therapeutics
Sponsored by Sarepta Therapeutics Inc.
Addressing a Gap in the Treatment of Dry Eye Disease
Room: Magnolia 5&6
Description: Dry Eye Disease (DED) is very common, but generally undertreated. There are over 18 million people in the US diagnosed with DED although it’s estimated that as many as 38 million are affected, however, only as few as 1.2 million are being actively treated with a prescription medication. DED is characterized by 2 main subtypes: Aqueous Deficient and Evaporative. Inflammation is common in both. Studies show up to 90% of ALL DED cases have an evaporative component, which represents a treatment gap and unmet need. MIEBO™ is the first and only prescription eye drop approved by FDA that specifically targets evaporation.
Faculty:
Jai Parekh, MD, MBA, FAAO
Co-Founder & CEO
EyeCare Consultants of NJ
Sponsored by Bausch+Lomb
VEOZAH (fezolinetant) for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause
Room: Magnolia 7&8
Description: In this session, we will review a new, FDA-approved treatment for moderate to severe vasomotor symptoms due to menopause, including indication, mechanism of action, and clinical safety and efficacy.
Faculty:
Steven McCarus, MD, FACOG
Chief, Division of Gynecologic Surgery, Advent Health
Sponsored by Astellas Pharma
